Loading clinical trials...
Loading clinical trials...
Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
Conditions
Interventions
Perampanel
Locations
24
United States
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
Birmingham, Alabama, United States
Barrow Neurological Institute
Phoenix, Arizona, United States
Arkansas Epilepsy Program
Little Rock, Arkansas, United States
UCSD Epilepsy Center
La Jolla, California, United States
Stanford Medical Center
Palo Alto, California, United States
UC Davis Medical Center
Sacramento, California, United States
Start Date
August 23, 2017
Primary Completion Date
April 27, 2021
Completion Date
April 27, 2021
Last Updated
May 16, 2022
NCT05667142
NCT06960811
NCT01830868
NCT02072824
NCT00655486
NCT01710657
Lead Sponsor
Eisai Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions